Aclarion, Inc.
$2.69
The Read: ACON's stock surged about 129% after Q2 2026 on narrower losses and strong commercialization gains including a second Weill Cornell deal and triple-digit Nociscan growth, but earlier Q1 2026 earnings with revenue misses and cash concerns led to muted or slight declines despite analyst upgrades.
ACON
Hover to view data
No Data